Atlas Trials

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

Clinical trial NCT01254578 · COMPLETED

Trial details

NCT number
NCT01254578
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2AAdult Acute Promyelocytic Leukemia With PML-RARAAdult Grade III Lymphomatoid GranulomatosisAdult Nasal Type Extranodal NK/T-Cell LymphomaAlkylating Agent-Related Acute Myeloid LeukemiaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Start date
2010-11-24
Primary completion
2012-11-09
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.